12-57747747-C-CT
Variant names:
Variant summary
Our verdict is Likely benign. The variant received -5 ACMG points: 0P and 5B. BS1_SupportingBS2
The NM_000075.4(CDK4):c.*777dupA variant causes a 3 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00653 in 151,274 control chromosomes in the GnomAD database, including 4 homozygotes. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Genomes: 𝑓 0.0054 ( 4 hom., cov: 31)
Exomes 𝑓: 0.041 ( 0 hom. )
Consequence
CDK4
NM_000075.4 3_prime_UTR
NM_000075.4 3_prime_UTR
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: -0.674
Genes affected
CDK4 (HGNC:1773): (cyclin dependent kinase 4) The protein encoded by this gene is a member of the Ser/Thr protein kinase family. This protein is highly similar to the gene products of S. cerevisiae cdc28 and S. pombe cdc2. It is a catalytic subunit of the protein kinase complex that is important for cell cycle G1 phase progression. The activity of this kinase is restricted to the G1-S phase, which is controlled by the regulatory subunits D-type cyclins and CDK inhibitor p16(INK4a). This kinase was shown to be responsible for the phosphorylation of retinoblastoma gene product (Rb). Mutations in this gene as well as in its related proteins including D-type cyclins, p16(INK4a) and Rb were all found to be associated with tumorigenesis of a variety of cancers. Multiple polyadenylation sites of this gene have been reported. [provided by RefSeq, Jul 2008]
TSPAN31 (HGNC:10539): (tetraspanin 31) The protein encoded by this gene is a member of the transmembrane 4 superfamily, also known as the tetraspanin family. Most of these members are cell-surface proteins that are characterized by the presence of four hydrophobic domains. The proteins mediate signal transduction events that play a role in the regulation of cell development, activation, growth and motility. This encoded protein is thought to be involved in growth-related cellular processes. This gene is associated with tumorigenesis and osteosarcoma. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Likely_benign. The variant received -5 ACMG points.
BS1
Variant frequency is greater than expected in population amr. GnomAdExome4 allele frequency = 0.0414 (202/4878) while in subpopulation AMR AF = 0.0558 (22/394). AF 95% confidence interval is 0.0378. There are 0 homozygotes in GnomAdExome4. There are 108 alleles in the male GnomAdExome4 subpopulation. Median coverage is 0. This position FAILED quality control check. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting
BS2
High AC in GnomAd4 at 786 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CDK4 | NM_000075.4 | c.*777dupA | 3_prime_UTR_variant | Exon 8 of 8 | ENST00000257904.11 | NP_000066.1 | ||
TSPAN31 | NM_005981.5 | c.*470dupT | 3_prime_UTR_variant | Exon 6 of 6 | ENST00000257910.8 | NP_005972.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00534 AC: 782AN: 146346Hom.: 3 Cov.: 31 show subpopulations
GnomAD3 genomes
AF:
AC:
782
AN:
146346
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.0414 AC: 202AN: 4878Hom.: 0 Cov.: 0 AF XY: 0.0454 AC XY: 108AN XY: 2378 show subpopulations
GnomAD4 exome
AF:
AC:
202
AN:
4878
Hom.:
Cov.:
0
AF XY:
AC XY:
108
AN XY:
2378
Gnomad4 AFR exome
AF:
AC:
1
AN:
78
Gnomad4 AMR exome
AF:
AC:
22
AN:
394
Gnomad4 ASJ exome
AF:
AC:
8
AN:
240
Gnomad4 EAS exome
AF:
AC:
21
AN:
626
Gnomad4 SAS exome
AF:
AC:
10
AN:
234
Gnomad4 FIN exome
AF:
AC:
0
AN:
16
Gnomad4 NFE exome
AF:
AC:
128
AN:
2998
Gnomad4 Remaining exome
AF:
AC:
11
AN:
266
⚠️ The allele balance in gnomAD4 Exomes is highly skewed (p-value = 0), which strongly suggests a high chance of mosaicism in these individuals.
Heterozygous variant carriers
0
18
36
55
73
91
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome AF: 0.00537 AC: 786AN: 146396Hom.: 4 Cov.: 31 AF XY: 0.00491 AC XY: 350AN XY: 71298 show subpopulations
GnomAD4 genome
AF:
AC:
786
AN:
146396
Hom.:
Cov.:
31
AF XY:
AC XY:
350
AN XY:
71298
Gnomad4 AFR
AF:
AC:
0.00206921
AN:
0.00206921
Gnomad4 AMR
AF:
AC:
0.00845378
AN:
0.00845378
Gnomad4 ASJ
AF:
AC:
0.00118064
AN:
0.00118064
Gnomad4 EAS
AF:
AC:
0.00198098
AN:
0.00198098
Gnomad4 SAS
AF:
AC:
0.00802603
AN:
0.00802603
Gnomad4 FIN
AF:
AC:
0.00184422
AN:
0.00184422
Gnomad4 NFE
AF:
AC:
0.00738805
AN:
0.00738805
Gnomad4 OTH
AF:
AC:
0.0100705
AN:
0.0100705
Heterozygous variant carriers
0
34
68
101
135
169
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Genome Het
Genome Hom
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Uncertain:1
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:not provided
- -
Cutaneous Malignant Melanoma, Dominant Uncertain:1
Jun 14, 2016
Illumina Laboratory Services, Illumina
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Mutation Taster
=100/0
polymorphism
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at